Daniel J Kagedan1, Ravish S Raju2, Matthew E Dixon3, Elizabeth Shin4, Qing Li5, Ning Liu5, Maryam Elmi1, Abraham El-Sedfy6, Lawrence Paszat7, Alexander Kiss8, Craig C Earle7, Nicole Mittmann9, Natalie G Coburn10. 1. Division of General Surgery, Department of Surgery, University of Toronto, Toronto, ON, Canada. 2. Sunnybrook Health Sciences Centre, Toronto, ON, Canada. 3. Department of Surgery, Maimonides Medical Center, Brooklyn, NY, USA. 4. Faculty of Medicine, University of Toronto, Toronto, ON, Canada. 5. Institute for Clinical Evaluative Sciences, Toronto, ON, Canada. 6. Department of Surgery, Saint Barnabas Medical Center, Livingston, NJ, USA. 7. Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Faculty of Medicine, University of Toronto, Toronto, ON, Canada; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada. 8. Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada; Institute of Health Policy, Management & Evaluation, University of Toronto, Toronto, ON, Canada. 9. Health Outcomes and PharmacoEconomic (HOPE) Research Centre, Sunnybrook Research Institute, Toronto, ON, Canada. 10. Division of General Surgery, Department of Surgery, University of Toronto, Toronto, ON, Canada; Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Faculty of Medicine, University of Toronto, Toronto, ON, Canada; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada; Institute of Health Policy, Management & Evaluation, University of Toronto, Toronto, ON, Canada. Electronic address: natalie.coburn@sunnybrook.ca.
Abstract
BACKGROUND: Using a retrospective observational cohort approach, the overall survival (OS) following curative-intent resection of pancreatic adenocarcinoma (PC) was defined at the population level according to adjuvant treatment, and predictors of OS were identified. METHODS: Patients undergoing resection of PC in the province of Ontario between 2005 and 2010 were identified using the provincial cancer registry, and linked to databases that include all treatments received and outcomes experienced in the province. Pathology reports were abstracted for staging and margin status. Patients were identified as having received chemotherapy (CT), chemoradiation therapy (CRT), or no adjuvant treatment (NAT). Kaplan-Meier survival analysis of patients surviving ≥ 6 months was performed, and predictors of OS identified by log-rank test. Cox multivariable analysis was used to define independent predictors of OS. RESULTS: Among the 473 patients undergoing PC resection, the median survival was 17.8 months; for the 397 who survived ≥ 6 months following surgery, the 5-year OS for the CT, CRT, and NAT groups was 21%, 16%, and 17%, respectively (p = 0.584). Lymph node-negative patients demonstrated improved OS associated with chemotherapy on multivariable analysis (HR = 2.20, 95% CI = 1.25-3.83 for NAT vs. CT). CONCLUSIONS: Following PC resection, only patients with negative lymph nodes demonstrated improved OS associated with adjuvant chemotherapy.
BACKGROUND: Using a retrospective observational cohort approach, the overall survival (OS) following curative-intent resection of pancreatic adenocarcinoma (PC) was defined at the population level according to adjuvant treatment, and predictors of OS were identified. METHODS:Patients undergoing resection of PC in the province of Ontario between 2005 and 2010 were identified using the provincial cancer registry, and linked to databases that include all treatments received and outcomes experienced in the province. Pathology reports were abstracted for staging and margin status. Patients were identified as having received chemotherapy (CT), chemoradiation therapy (CRT), or no adjuvant treatment (NAT). Kaplan-Meier survival analysis of patients surviving ≥ 6 months was performed, and predictors of OS identified by log-rank test. Cox multivariable analysis was used to define independent predictors of OS. RESULTS: Among the 473 patients undergoing PC resection, the median survival was 17.8 months; for the 397 who survived ≥ 6 months following surgery, the 5-year OS for the CT, CRT, and NAT groups was 21%, 16%, and 17%, respectively (p = 0.584). Lymph node-negative patients demonstrated improved OS associated with chemotherapy on multivariable analysis (HR = 2.20, 95% CI = 1.25-3.83 for NAT vs. CT). CONCLUSIONS: Following PC resection, only patients with negative lymph nodes demonstrated improved OS associated with adjuvant chemotherapy.
Authors: Mary Kay Washington; Jordan Berlin; Philip A Branton; Lawrence J Burgart; David K Carter; Carolyn C Compton; Wendy L Frankel; J Milburn Jessup; Sanjay Kakar; Bruce Minsky; Raouf E Nakhleh; Jean-Nicolas Vauthey Journal: Arch Pathol Lab Med Date: 2010-04 Impact factor: 5.534
Authors: William F Regine; Kathryn A Winter; Ross Abrams; Howard Safran; John P Hoffman; Andre Konski; Al B Benson; John S Macdonald; Tyvin A Rich; Christopher G Willett Journal: Ann Surg Oncol Date: 2011-03-10 Impact factor: 5.344
Authors: Javairiah Fatima; Thomas Schnelldorfer; Joshua Barton; Christina M Wood; Heather J Wiste; Thomas C Smyrk; Lizhi Zhang; Michael G Sarr; David M Nagorney; Michael B Farnell Journal: Arch Surg Date: 2010-02
Authors: Jason B Fleming; Ricardo J Gonzalez; Maria Q B Petzel; E Lin; Jeffrey S Morris; Henry Gomez; Jeffrey E Lee; Christopher H Crane; Peter W T Pisters; Douglas B Evans Journal: Arch Surg Date: 2009-03
Authors: Nipun B Merchant; Jennifer Rymer; Elizabeth A S Koehler; G Daniel Ayers; Jason Castellanos; David A Kooby; Sharon H Weber; Clifford S Cho; C Max Schmidt; Atilla Nakeeb; Jesus M Matos; Charles R Scoggins; Robert C G Martin; Hong Jin Kim; Syed A Ahmad; Carrie K Chu; Rebecca McClaine; Brian K Bednarski; Charles A Staley; Kenneth Sharp; Alexander A Parikh Journal: J Am Coll Surg Date: 2009-03-26 Impact factor: 6.113
Authors: Michele M Corsini; Robert C Miller; Michael G Haddock; John H Donohue; Michael B Farnell; David M Nagorney; Aminah Jatoi; Robert R McWilliams; George P Kim; Sumita Bhatia; Matthew J Iott; Leonard L Gunderson Journal: J Clin Oncol Date: 2008-07-20 Impact factor: 44.544
Authors: H Ueno; T Kosuge; Y Matsuyama; J Yamamoto; A Nakao; S Egawa; R Doi; M Monden; T Hatori; M Tanaka; M Shimada; K Kanemitsu Journal: Br J Cancer Date: 2009-08-18 Impact factor: 7.640
Authors: Marita D Bauman; David G Becerra; E Molly Kilbane; Nicholas J Zyromski; C Max Schmidt; Henry A Pitt; Attila Nakeeb; Michael G House; Eugene P Ceppa Journal: Surg Endosc Date: 2017-06-22 Impact factor: 4.584